Baird analyst Joel Beatty raised the firm’s price target on Immutep (IMMP) to $7 from $6 and keeps an Outperform rating on the shares. The firm raised its target after the company announced investigator initiated INSIGHT-003 study data today for their lead agent eftilagimod alpha (efti).
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks